This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Toll-Like Receptor (TLR) signaling can reprogram an inflammatory (injurious) response to stroke into a neuroprotective response in the brain. Agonists of TLRs 9 and 7 (CpG ODNs and imiquimod ?IMQ, respectively) are lead compounds for prophylactic neuroprotection against stroke. Clinical translational failures from rodent to human prompted additional preclinical evaluation. Using a primate stroke model we aim to establish essential effacy and pharmacokinetic data. Our preliminary studies support development of neuroprotective strategies for high-risk stroke patients to be further tested in the non-human primate via:
Aim 1. Determine the optimal dose to achieve neuroprotective efficacy with TLR9 (K-and D-mix CpG ODNs) and TLR7 (IMQ) candidate drugs as prophylactic therapy in a NHP model of cortical stroke.
Aim 2. Determine the time window of neuroprotective efficacy for the optimal drug in male NHP stroke model.
Aim 3. Determine neuroprotective efficacy as prophylactic therapy in aged NHP.
Aim 4. Determine the neuroprotective efficacy of repeated in a NHP model of cortical stroke.
Aim 5. Determine the neuroprotective efficacy of the optimal drug as prophylactic stroke therapy in female NHPs.
Aim 6. Determine pharmacokinetic and toxicity profiles.
Aim 7. Submit an IND application for the optimal candidate based on efficacy, pharmacokinetics and toxicity. Progress:
Aim 1 studies are near completion, although the blinded study design, while optimal, prevents any preliminary analysis of the data collected so far.
|Su, Weiping; Foster, Scott C; Xing, Rubing et al. (2017) CD44 Transmembrane Receptor and Hyaluronan Regulate Adult Hippocampal Neural Stem Cell Quiescence and Differentiation. J Biol Chem 292:4434-4445|
|Lima, Fernanda B; Leite, Cristiane M; Bethea, Cynthia L et al. (2017) Progesterone increased ?-endorphin innervation of the locus coeruleus, but ovarian steroids had no effect on noradrenergic neurodegeneration. Brain Res 1663:1-8|
|Slayden, Ov Daniel (2016) Translational In Vivo Models for Women's Health: The Nonhuman Primate Endometrium--A Predictive Model for Assessing Steroid Receptor Modulators. Handb Exp Pharmacol 232:191-202|
|Chadderdon, S M; Belcik, J T; Bader, L et al. (2016) Vasoconstrictor eicosanoids and impaired microvascular function in inactive and insulin-resistant primates. Int J Obes (Lond) 40:1600-1603|
|Dufour, Brett D; McBride, Jodi L (2016) Intravascular AAV9 Administration for Delivering RNA Silencing Constructs to the CNS and Periphery. Methods Mol Biol 1364:261-75|
|Meyer, Thomas J; Held, Ulrike; Nevonen, Kimberly A et al. (2016) The Flow of the Gibbon LAVA Element Is Facilitated by the LINE-1 Retrotransposition Machinery. Genome Biol Evol 8:3209-3225|
|Pleil, Kristen E; Helms, Christa M; Sobus, Jon R et al. (2016) Effects of chronic alcohol consumption on neuronal function in the non-human primate BNST. Addict Biol 21:1151-1167|
|Mohiuddin, Muhammad M; Singh, Avneesh K; Corcoran, Philip C et al. (2016) Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. Nat Commun 7:11138|
|Sylwester, Andrew; Nambiar, Kate Z; Caserta, Stefano et al. (2016) A new perspective of the structural complexity of HCMV-specific T-cell responses. Mech Ageing Dev 158:14-22|
|Laws, L H; Parker, C E; Cherala, G et al. (2016) Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion. Am J Transplant 16:3139-3149|
Showing the most recent 10 out of 481 publications